VanEck Biotech ETF

BBH
ETF Ticker

+27.05%

+38.34%

NASDAQ

Equity

United States

Sector

ETF Strategy Fund Grade AA

The VanEck Biotech ETF, BBH_US, is listed on the NASDAQ and tracks the MVIS US Listed Biotech 25 index. The fund provides exposure to United States, Sector Equity and has assets under management of $469.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Dec 20, 2011. It has a net expense ratio of 35bps. (All data in USD as of Oct 9, 2026 unless stated.)

The underlying MVIS US Listed Biotech 25 Index targets the largest and most liquid US-listed biotechnology companies. Eligibility requires ≥50% revenue from biotechnology activities (25% for current members), US exchange listing, free float ≥10% (5% for incumbents), full market cap > USD 150m (USD 75m for incumbents), three-month ADTV ≥ USD 1m in each of the current and prior two quarters (≥ USD 0.2m for incumbents in two of three), and ≥0.25m shares traded per month over six months. At reconstitution, the 50 biggest names form a candidate set, ranked by free-float market cap and 3-month ADTV; the top 10 enter, with 15 more chosen from ranked 11–40 incumbents to reach 25. Weighting is modified free-float market cap: “Large-Weights” (≥5 and ≤10 names) collectively capped at 50%, single-name caps 20%/min 5%; “Small-Weights” capped 4.5% per name, with non-pure-play aggregate ≤20%. Reconstitution occurs in March/September; weights rebalance quarterly.

ETF Details

Key Facts

Issuer:
VanEck
AUM:
$469.0m (as of Aug 31, 2026)
Net Expense Ratio:
35 bps
Inception Date:
Dec 20, 2011
Index:
MVIS US Listed Biotech 25 Index
Dividend Frequency:
Annually

Trading

Ticker:
BBH
Exchange:
NASDAQ
ISIN:
US92189F7261
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
United States
Theme:
Sector
Economic Development:
Developed Markets
1 Year Volatility:
22.05%
3 Year Volatility:
20.49%
5 Year Volatility:
21.77%

Performance

TTM Dividend Yield:
0.55% (verify with issuer)
1 Month Performance:
4.00%
3 Month Performance:
14.44%
6 Month Performance:
26.85%
1 Year Performance:
38.34%
3 Year Performance:
57.30%
5 Year Performance:
28.38%
Investment Proposition

VanEck Biotech ETF (BBH) targets concentrated exposure to biotechnology innovators focused on drug discovery, clinical development, and commercial therapeutics. The approach centers on scaled and emerging franchises across therapeutic areas, aiming to capture the sector’s asymmetric payoff profile where successful approvals and strategic activity can drive outsized value creation. Performance is driven by pipeline progress, regulatory outcomes, intellectual-property durability, and funding conditions; periods of supportive capital markets and constructive risk appetite typically favor the group, while higher discount rates or setbacks in pivotal trials can weigh on valuations. Factor characteristics often exhibit high growth and momentum with low current profitability and elevated idiosyncratic volatility, making diversification and position sizing important. Within portfolios, BBH can serve as a thematic growth satellite, a targeted innovation sleeve complementing broader healthcare, or a potential portfolio-alpha source when clinical catalysts cluster. Suitable investors include research-oriented growth allocators comfortable with binary event risk and long-horizon institutions seeking exposure to medical innovation cycles. Adding exposure can be timely when valuation resets coincide with robust late-stage pipelines. A key risk to monitor is concentration in a limited set of pipeline-dependent companies, which can magnify stock-specific outcomes.

ETF Analytics

Fund Discovery

4 Suggestions